User profiles for "author:Pär-Ola Bendahl"
Pär-Ola BendahlAssociate Professor, Lund University Verified email at med.lu.se Cited by 12374 |
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
MP Look, WLJ Van Putten, MJ Duffy… - Journal of the …, 2002 - academic.oup.com
Background: Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play
essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are …
essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are …
[HTML][HTML] The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Introduction Human breast tumors are heterogeneous and consist of phenotypically diverse
cells. Breast cancer cells with a CD44+/CD24-phenotype have been suggested to have …
cells. Breast cancer cells with a CD44+/CD24-phenotype have been suggested to have …
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
LH Saal, P Johansson, K Holm… - Proceedings of the …, 2007 - National Acad Sciences
Pathway-specific therapy is the future of cancer management. The oncogenic
phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in solid tumors; …
phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in solid tumors; …
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
E Olsson, C Winter, A George, Y Chen… - EMBO molecular …, 2015 - embopress.org
Metastatic breast cancer is usually diagnosed after becoming symptomatic, at which point it
is rarely curable. Cell‐free circulating tumor DNA (ct DNA) contains tumor‐specific …
is rarely curable. Cell‐free circulating tumor DNA (ct DNA) contains tumor‐specific …
[HTML][HTML] CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers
Background The CD44 cell adhesion molecule is aberrantly expressed in many breast
tumors and has been implicated in the metastatic process as well as in the putative cancer …
tumors and has been implicated in the metastatic process as well as in the putative cancer …
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
O Bjarnadottir, Q Romero, PO Bendahl… - Breast cancer research …, 2013 - Springer
Lipophilic statins purportedly exert anti-tumoral effects on breast cancer by decreasing
proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting …
proliferation and increasing apoptosis. HMG-CoA reductase (HMGCR), the rate-limiting …
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas
M Jönsson, J Dejmek, PO Bendahl, T Andersson - Cancer research, 2002 - AACR
Previous in vitro studies have implied that the Wnt-5a gene plays a role as a tumor
suppressor. To explore the clinical relevance of this concept, 96 primary invasive breast …
suppressor. To explore the clinical relevance of this concept, 96 primary invasive breast …
[HTML][HTML] Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential
P Francis, HM Namløs, C Müller, P Edén, J Fernebro… - BMC genomics, 2007 - Springer
Background Soft tissue sarcoma (STS) diagnosis is challenging because of a multitude of
histopathological subtypes, different genetic characteristics, and frequent intratumoral …
histopathological subtypes, different genetic characteristics, and frequent intratumoral …
Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma
SK Gruvberger-Saal, PO Bendahl, LH Saal… - Clinical Cancer …, 2007 - AACR
Purpose: Endocrine therapies, such as tamoxifen, are commonly given to most patients with
estrogen receptor (ERα)–positive breast carcinoma but are not indicated for persons with …
estrogen receptor (ERα)–positive breast carcinoma but are not indicated for persons with …
Should all patients with non–muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective …
S Gudjónsson, L Adell, F Merdasa, R Olsson… - European urology, 2009 - Elsevier
BACKGROUND: To decrease recurrences in non–muscle-invasive bladder cancer (NMIBC),
the European Association of Urology (EAU) guidelines recommend immediate, intravesical …
the European Association of Urology (EAU) guidelines recommend immediate, intravesical …